Home / Bioanalytical and biomarker services / Translational strategy consulting / Regulatory guidance
Regulatory Strategy Consulting
Expert regulatory strategy consulting designed to align your rare disease bioassays and clinical endpoints with stringent FDA and EMA expectations.
Clear pathways for accelerated approval
We provide direct advisory input to ensure your rare disease program generates defensible data. Our senior scientists help you establish the exact context of use early, so every bioassay outcome satisfies rigorous agency scrutiny and supports your regulatory strategy.
Submission-ready data packages
We leverage decades of rare disease research to help you define primary and secondary biomarker endpoints that regulators trust.
Context of use alignment
We evaluate your study design to ensure your bioassay selection remains strictly fit for purpose and in alignment with regulatory requirements.
Accelerated approval strategies
We advise on primary biomarker outcomes specifically for small cohorts to support efficient agency reviews and accelerated pathways.
Audit readiness preparation
We operate within rigorous standard operating procedures designed to withstand intense sponsor and FDA scrutiny.
Discuss your regulatory strategy
Engage our experts to align your rare disease clinical endpoints with clear agency expectations.
Deep familiarity across global regulatory standards
AGADA Biosciences applies focused expertise to the disciplined execution of your program. We understand the unique challenges of rare disease development and deliver guidance that translates into data regulators trust.
Global compliance:
We operate with deep familiarity across FDA and EMA regulations to ensure your data remains interpretable worldwide.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
FDA approval history:
Our quality assessments directly supported a successful FDA audit, leading to approval of a rare disease drug.
Primary outcome focus:
We help define critical endpoints that carry significant statistical weight in small rare disease cohorts.
Fast escalation paths for crucial decisions
Our lean model keeps scientific expertise close to the work, ensuring prompt advisory input during your regulatory planning phase.
Built to integrate
AGADA Biosciences acts as a collaborative partner that integrates smoothly into your existing vendor ecosystem. We provide strategic guidance and clarify ownership across multi-site trials without demanding total control of your program.
Direct access to senior scientific leadership
You work directly with the decision-makers, guiding your rare disease program so operational challenges are resolved in minutes rather than weeks.
Strategic advisory:
Our team provides targeted input on your regulatory strategy before laboratory work begins, helping prevent costly downstream rework.
Shared-cost model:
We provide pre-validated bioassays that satisfy FDA requirements and save sponsors months of internal validation time.
Clear accountability:
We clarify ownership of critical trial steps and manage specialized workflows alongside your other partners.
Submission readiness:
You receive defensible data packages generated through strict adherence to GCP and GLP guidelines.
Start a conversation
Reach out to our team to align your rare disease study design with strict agency expectations.
Take a virtual tour of our Halifax facility
Explore our state-of-the-art laboratory and discover how our team manages samples from receipt through to analysis and release. In this virtual tour, you’ll see how we apply Good Clinical Practice and relevant bioanalytical regulatory expectations to protect sample integrity, carry out validated bioanalytical work and support dependable data.
Quality and compliance
We operate in strict compliance with GCP, GLP and GDPR regulations to ensure your data remains interpretable and defensible. Every team member must hold a CITI certification before supporting any sponsor trial.
Meet our scientific leadership
Our founders and senior scientists are globally recognized leaders in rare and neuromuscular disease research, bringing decades of specialized expertise to your program.
